Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [(177)Lu]Lu-PSMA I&T during long-term follow-up

por Hartrampf, Philipp E., Seitz, Anna Katharina, Weinzierl, Franz-Xaver, Serfling, Sebastian E., Schirbel, Andreas, Rowe, Steven P., Kübler, Hubert, Buck, Andreas K., Werner, Rudolf A.
Publicado 2022

mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease

por Hartrampf, Philipp E., Bundschuh, Ralph A., Weinzierl, Franz-Xaver, Serfling, Sebastian E., Kosmala, Aleksander, Seitz, Anna Katharina, Kübler, Hubert, Buck, Andreas K., Essler, Markus, Werner, Rudolf A.
Publicado 2022

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [(177)Lu]Lu-PSMA I&T

por Hartrampf, Philipp E., Weinzierl, Franz-Xaver, Serfling, Sebastian E., Pomper, Martin G., Rowe, Steven P., Higuchi, Takahiro, Seitz, Anna Katharina, Kübler, Hubert, Buck, Andreas K., Werner, Rudolf A.
Publicado 2022

Early biochemical and radiographic response after one cycle of [(177)Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients

por Cytawa, Wojciech, Hendel, Robin, Tomasik, Bartłomiej, Weinzierl, Franz-Xaver, Bley, Thorsten, Jassem, Jacek, Schirbel, Andreas, Buck, Andreas K., Bundschuh, Ralph A., Hartrampf, Philipp E., Werner, Rudolf A., Lapa, Constantin
Publicado 2023

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

por Hartrampf, Philipp E., Weinzierl, Franz-Xaver, Buck, Andreas K., Rowe, Steven P., Higuchi, Takahiro, Seitz, Anna Katharina, Kübler, Hubert, Schirbel, Andreas, Essler, Markus, Bundschuh, Ralph A., Werner, Rudolf A.
Publicado 2022